Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Candriam S.C.A.

Candriam S.C.A. lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 403,026 shares of the company’s stock after buying an additional 30,021 shares during the quarter. Candriam S.C.A.’s holdings in Mirum Pharmaceuticals were worth $29,546,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MCF Advisors LLC raised its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Mirum Pharmaceuticals by 27.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 6,802 shares of the company’s stock valued at $499,000 after acquiring an additional 1,473 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Mirum Pharmaceuticals by 242.4% during the 3rd quarter. Penserra Capital Management LLC now owns 26,479 shares of the company’s stock valued at $1,941,000 after acquiring an additional 18,746 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at approximately $205,000. Finally, Jones Financial Companies Lllp lifted its stake in Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares during the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on MIRM. Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Stifel Nicolaus increased their target price on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $107.25.

Mirum Pharmaceuticals Stock Up 0.1%

MIRM stock opened at $100.54 on Tuesday. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $105.74. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of -116.91 and a beta of 0.49. The firm’s 50-day moving average is $83.88 and its two-hundred day moving average is $74.69. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 1,053 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $101,288.07. Following the completion of the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This trade represents a 2.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the transaction, the chief executive officer owned 160,294 shares in the company, valued at approximately $16,558,370.20. This trade represents a 5.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,136 shares of company stock valued at $4,352,029 over the last three months. 22.87% of the stock is owned by company insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.